SNIPR Biome receives funding for the development of CRISPR-medicines to improve Environmental Enteric Dysfunction (EED) in pregnant women
28 juin 2024 02h50 HE
|
SNIPR BIOME
SNIPR BIOME receives funding from the Bill & Melinda Gates Foundation to accelerate the development of SNIPR Biome's microbial gene therapy platform.
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
22 avr. 2024 07h00 HE
|
SNIPR Biome
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase 1b/2a trial will evaluate SNIPR001 for the...
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
22 avr. 2024 02h00 HE
|
SNIPR Biome
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase 1b/2a trial will evaluate SNIPR001 for the...
SNIPR Biome Launches A Non-Profit Patent Licensing Program To Enable The Field of CRISPR Editing in Prokaryotes
03 oct. 2022 07h00 HE
|
SNIPR Biome
SNIPR Biome Launches A Non-Profit Patent Licensing Program To Enable The Field of CRISPR Editing in Prokaryotes Copenhagen, October 03, 2022: SNIPR Biome ApS (“SNIPR” or “the Company”), a company...
SNIPR Biome Launches A Non-Profit Patent Licensing Program To Enable The Field of CRISPR Editing in Prokaryotes
03 oct. 2022 02h00 HE
|
SNIPR Biome
SNIPR Biome Launches A Non-Profit Patent Licensing Program To Enable The Field of CRISPR Editing in Prokaryotes Copenhagen, October 03, 2022: SNIPR Biome ApS (“SNIPR” or “the Company”), a company...
SNIPR Biome Granted New US Patent Covering Lytic CRISPR Phage
02 août 2022 02h00 HE
|
SNIPR Biome
SNIPR Biome Granted New US Patent Covering Lytic CRISPR Phage Copenhagen, August 2nd, 2022: SNIPR Biome ApS (or “the Company”), a clinical-stage biotechnology company developing CRISPR-based...